This trade activity should not be overlooked: Repligen Corporation (RGEN)

Repligen Corporation (NASDAQ: RGEN) stock fell -3.57% on Tuesday to $183.99 against a previous-day closing price of $190.81. With 0.77 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.59 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $188.73 whereas the lowest price it dropped to was $175.92. The 52-week range on RGEN shows that it touched its highest point at $262.26 and its lowest point at $137.21 during that stretch. It currently has a 1-year price target of $225.55. Beta for the stock currently stands at 1.08.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RGEN was down-trending over the past week, with a drop of -0.90%, but this was up by 8.71% over a month. Three-month performance surged to 10.15% while six-month performance fell -6.64%. The stock gained 0.10% in the past year, while it has gained 8.67% so far this year. A look at the trailing 12-month EPS for RGEN yields 2.89 with Next year EPS estimates of 2.97. For the next quarter, that number is 0.58. This implies an EPS growth rate of 101.50% for this year and -6.52% for next year. EPS is expected to grow by 35.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 45.60%.

Float and Shares Shorts:

At present, 55.50 million RGEN shares are outstanding with a float of 55.31 million shares on hand for trading. On Oct 13, 2022, short shares totaled 2.97 million, which was 5.35% higher than short shares on Sep 14, 2022. In addition to Mr. Anthony J. Hunt as the firm’s Pres, CEO & Director, Mr. Jon K. Snodgres serves as its Chief Financial Officer.


Institutional Ownership:

Through their ownership of 93.28% of RGEN’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 61.69% of RGEN, in contrast to 31.42% held by mutual funds. Shares owned by individuals account for 17.51%. As the largest shareholder in RGEN with 9.11% of the stake, The Vanguard Group, Inc. holds 5,056,034 shares worth 5,056,034. A second-largest stockholder of RGEN, BlackRock Fund Advisors, holds 4,585,904 shares, controlling over 8.26% of the firm’s shares. T. Rowe Price Associates, Inc. is the third largest shareholder in RGEN, holding 3,659,579 shares or 6.59% stake. With a 6.40% stake in RGEN, the T Rowe Price New Horizons Fund is the largest stakeholder. A total of 3,554,308 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 3.04% of RGEN stock, is the second-largest Mutual Fund holder. It holds 1,687,930 shares valued at 285.78 million. iShares Core S&P Mid Cap ETF holds 2.87% of the stake in RGEN, owning 1,593,104 shares worth 269.73 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RGEN since 12 analysts follow the stock currently. There are 9 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With RGEN analysts setting a high price target of $270.00 and a low target of $180.00, the average target price over the next 12 months is $225.55. Based on these targets, RGEN could surge 46.75% to reach the target high and fall by -2.17% to reach the target low. Reaching the average price target will result in a growth of 22.59% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. RGEN will report FY 2022 earnings on 02/15/2024. Analysts have provided yearly estimates in a range of $3.28 being high and $3.15 being low. For RGEN, this leads to a yearly average estimate of $3.19. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Repligen Corporation surprised analysts by $0.09 when it reported $0.77 EPS against a consensus estimate of $0.68. The surprise factor in the prior quarter was $0.20. Based on analyst estimates, the high estimate for the next quarter is $0.63 and the low estimate is $0.55. The average estimate for the next quarter is thus $0.58.

Summary of Insider Activity:

Insiders traded RGEN stock several times over the past three months with 1 Buys and 1 Sells. In these transactions, 25,000 shares were bought while 25,000 shares were sold. The number of buy transactions has increased to 33 while that of sell transactions has risen to 50 over the past year. The total number of shares bought during that period was 145,744 while 151,746 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *